Braveheart Bio, Inc.

Braveheart Bio is a drug development company working on treatments for heart diseases, particularly hypertrophic cardiomyopathy, a condition where the heart muscle becomes thickened and doesn't pump blood efficiently. The company is testing experimental medicines called cardiac myosin inhibitors, which work by targeting a protein in heart muscle cells that controls how the heart contracts. These drugs are still in clinical testing stages, meaning they are being studied in patients but have not yet been approved by regulators. The company was founded in 2024 and is based in San Francisco.